XORTX Therapeutics is focused on developing innovative therapies aimed at treating progressive kidney diseases, particularly those associated with aberrant purine metabolism and elevated uric acid levels. The company is advancing three primary programs: XRx-008, XRx-101, and XRx-225. XRx-008 is a novel formulation designed to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), a genetic disorder that leads to declining kidney function. This therapy utilizes Oxypurinol, a well-studied xanthine oxidase inhibitor, to lower uric acid levels, which has been identified as a significant risk factor for disease progression in ADPKD. XRx-225 targets Type 2 Diabetic Nephropathy, a common cause of chronic kidney failure, by addressing the underlying metabolic issues associated with diabetes and its complications.

Additionally, XORTX is developing XRx-101, a proprietary formulation aimed at reducing acute kidney injury linked to coronavirus infections, including COVID-19. This program is based on the observation that elevated uric acid levels are frequently observed in patients with acute kidney injury during severe viral infections. By lowering uric acid, XRx-101 aims to mitigate the renal and systemic complications associated with such infections. The company emphasizes the importance of strategic collaborations and a robust patent portfolio to enhance its capabilities in bringing these novel therapies to market, ultimately aiming to improve the quality of life for patients suffering from these serious conditions.

Canada

XORTX Therapeutics Inc. is a late stage clinical pharmaceutical company dedicated to developing new therapies for progressive kidney disease. The company has two clinically advanced products in development, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). XORTX Therapeutics Inc. is also focused on developing innovative therapies to treat progressive kidney disease, with three drug development programs, two of which are clinically advanced products under development.

XORTX Therapeutics

Company Details